B Cell Lymphoma
Conference Coverage
Cell count ratios appear to predict thromboembolism in lymphoma
AMSTERDAM – The findings mean clinicians can look to complete blood count for answers on thromboembolism risk.
News
Hedgehog signaling offers prognostic, therapeutic potential in CLL
Hedgehog signaling was associated with expression of GLI1, which could be a future therapeutic target.
News
BET inhibitors may target oncogene in ABC-like DLBCL
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
Conference Coverage
Obinutuzumab provides strong early responses in untreated MCL
AMSTERDAM – A minimal residual disease rate as high as 85% is “unprecedented” in this population of patients, the lead investigator of the LYMA-...
Conference Coverage
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Conference Coverage
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
Conference Coverage
Inhibitor produces high response rate in relapsed/refractory FL
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...
News
FDA approves Polivy for DLBCL
The FDA approval is based on results of an open-label, multicenter clinical trial of 80 patients with DLBCL who had undergone at least one prior...